The Conversation (0)
- WORLD EDITIONAustraliaNorth AmericaWorld
April 28, 2025
Alert Options
No alert set
INN Article Notification
Alert Option
You will be notified when this event occurs. No additional settings needed.
29 August 2025
Appendix 4E and Preliminary Final Report
Radiopharm Theranostics (RAD:AU) has announced Appendix 4E and Preliminary Final ReportDownload the PDF here. Keep Reading...
29 July 2025
Quarterly Activities/Appendix 4C Cash Flow Report
Radiopharm Theranostics (RAD:AU) has announced Quarterly Activities/Appendix 4C Cash Flow ReportDownload the PDF here. Keep Reading...
27 July 2025
RAD receives IND approval from US FDA for Betabart (RV-01)
Radiopharm Theranostics (RAD:AU) has announced RAD receives IND approval from US FDA for Betabart (RV-01)Download the PDF here. Keep Reading...
10 June 2025
RAD Granted US FDA Fast Track for RAD101 Metastases Imaging
Radiopharm Theranostics (RAD:AU) has announced RAD Granted US FDA Fast Track for RAD101 Metastases ImagingDownload the PDF here. Keep Reading...
03 June 2025
RAD Doses 1st Patient in Therapeutic Trial of 177Lu-RAD202
Radiopharm Theranostics (RAD:AU) has announced RAD Doses 1st Patient in Therapeutic Trial of 177Lu-RAD202Download the PDF here. Keep Reading...
27 July
Biotech and Pharma Market Trends: Q2 2026 Review and Forecast
Biotech is starting to edge back into focus as investors reassess the durability of the artificial intelligence (AI) trade and look for sectors where AI is producing tangible operational gains. “There are concerns that we’re in an AI bubble, and I think money is starting to go from companies... Keep Reading...
22 July
Top 5 Small-cap Biotech Stocks in 2026
The NASDAQ Biotechnology Index (INDEXNASDAQ:NBI) has climbed back to multi-year highs in 2026, underscoring renewed strength in the biotech sector despite broader market volatility. As of July 7, the index stood at 6,856.74, up over 20 percent year-to-date. The rise shows that investors are... Keep Reading...
06 July
Lexaria Updates Business Development
(TheNewswire) Kelowna, British Columbia July 6, 2026 TheNewswire Lexaria Bioscience Corp. (Nasdaq: LEXX) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, is pleased to have experienced many positive meetings with potential pharmaceutical partners and collaborators at... Keep Reading...
06 July
Lexaria Updates Business Development
KELOWNA, BC / ACCESS Newswire / July 6, 2026 / Lexaria Bioscience Corp. (NASDAQ:LEXX) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, is pleased to have experienced many positive meetings with potential pharmaceutical partners and collaborators at the 2026 BIO... Keep Reading...
25 June
Lexaria's Human Study GLP-1-H26-7 Has Begun Dosing on Schedule
KELOWNA, BC / ACCESS Newswire / June 25, 2026 / Lexaria Bioscience Corp. (NASDAQ:LEXX) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, announces that dosing began on schedule on June 14th with Human Pilot Study #7 (GLP-1-H26-7) that is evaluating two oral... Keep Reading...
23 June
Lexaria's Animal Study GLP-1-A26-1 Has Begun Dosing on Schedule
Potentially Valuable Novel Compositions Being InvestigatedLexaria Also Receives Additional New Granted Patent KELOWNA, BC / ACCESS Newswire / June 23, 2026 / Lexaria Bioscience Corp. (NASDAQ:LEXX) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, provides the following... Keep Reading...
Latest News
Interactive Chart
Latest Press Releases
Related News
TOP STOCKS
American Battery4.030.24
Aion Therapeutic0.10-0.01
Cybin Corp2.140.00